<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05109897</url>
  </required_header>
  <id_info>
    <org_study_id>2021-08-014B</org_study_id>
    <nct_id>NCT05109897</nct_id>
  </id_info>
  <brief_title>Influencing Factors on Gait Variability in PD</brief_title>
  <official_title>Influencing Factors and Improving Strategy on Gait Variability in People With Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Yang Ming University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Yang Ming University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The principal motor features of Parkinson's disease (PD) include rigidity, tremor,&#xD;
      bradykinesia, and postural instability. These motor deficits might cause gait dysfunction&#xD;
      including reduced gait velocity, stride length, arm swing, and increased gait variability.&#xD;
      Among these, increase in gait variability increased fall risk and served as a marker of&#xD;
      disease progression. Previous studies reported that some factors might influence gait&#xD;
      variability. However, which one contributes most has not yet been verified. Therefore, the&#xD;
      purpose of the present study is to identify the more related influencing factors on gait&#xD;
      variability in people with PD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Gait variability</measure>
    <time_frame>10 minutes</time_frame>
    <description>Using GAITRite system to measure coefficient of variation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Walking speed</measure>
    <time_frame>10 minutes</time_frame>
    <description>Using GAITRite system to evaluate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sensory organization test</measure>
    <time_frame>20 minutes</time_frame>
    <description>Using NeuroCom Smart Balance Master to measure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part III of the Unified Parkinson's Disease Rating Scale</measure>
    <time_frame>20 minutes</time_frame>
    <description>The score ranged from 0 to 72. Higher scores show increased severity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tinetti Balance Scale</measure>
    <time_frame>10 minutes</time_frame>
    <description>The score ranged from 0 to 28. Higher scores show better balance.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>New freezing of gait questionnaire</measure>
    <time_frame>15 minutes</time_frame>
    <description>The score ranged from 0 to 29. Higher scores show increased severity in freezing of gait.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Montreal Cognitive Assessment</measure>
    <time_frame>20 minutes</time_frame>
    <description>The score ranged from 0 to 30. Higher scores show better cognitive function.</description>
  </primary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Parkinson Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        People with Parkinson's disease&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Idiopathic PD&#xD;
&#xD;
          -  Hoehn and Yahr stages I through III&#xD;
&#xD;
          -  Ability to stand and walk 5 m independently with or without any walking aids&#xD;
&#xD;
          -  Stable medication usage&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unstable medical conditions&#xD;
&#xD;
          -  Any neurological, cardiopulmonary or orthopedic problem/diseases that may interfere&#xD;
             with participating the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yea-Ru Yang, PhD</last_name>
    <phone>886228267279</phone>
    <email>yryang@nycu.edu.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Physical Therapy and Assistive Technology, National Yang Ming Chiao Tung University</name>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 13, 2021</study_first_submitted>
  <study_first_submitted_qc>October 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2021</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Yang Ming University</investigator_affiliation>
    <investigator_full_name>Yea-Ru Yang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Parkinson's disease, Gait variability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

